New combo therapy aims to shrink lymphoma with less radiation
NCT ID NCT03341520
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received low-dose radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination could achieve complete remission while reducing side effects. The study enrolled 89 adults with untreated stage I or II disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I FOLLICULAR LYMPHOMA GRADE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Klinikum Kempten
Kempten, Germany
-
LMU
Munich, 81377, Germany
-
Site Marburg
Marburg, Germany
-
TU
Munich, 81675, Germany
-
University of Cologne
Cologne, 50924, Germany
-
University of Essen
Essen, 45122, Germany
-
University of Frankfurt
Frankfurt, 60590, Germany
-
University of Heidelberg
Heidelberg, 69120, Germany
-
University of Muenster
Münster, Germany
-
University of Tuebingen
Tübingen, Baden-Wurttemberg, Germany
-
University of Ulm
Ulm, 89081, Germany
-
Vivantes Klinikum
Berlin, Germany